Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
Benjamin Besse Puts Krascendo1 Results of Divarasib into Perspective at ...
Genentech: Press Releases | Genentech’s divarasib demonstrated best-in ...
How Does Divarasib Compare With Other KRAS Inhibitors in NSCLC ...
Roche's lung cancer drug divarasib shows impressive data | STAT
Divarasib in Previously Treated Advanced KRAS G12C–Mutated NSCLC - The ...
Roche's Divarasib Beats Two Approved KRAS Drugs on Survival - YouTube
Divarasib lung cancer trial: why the comparison group matters - YouTube
Roche’s divarasib demonstrated best-in-class efficacy, advancing the ...
Roche Aktie: Divarasib senkt Sterberisiko um 44 Prozent
Divarasib | Ras | TargetMol
Roche Reports Positive Phase 3 Results for Divarasib in Previously ...
The Evolution of Divarasib in KRAS G12C-Mutant NSCLC · Cancer Treatment ...
Divarasib beats approved KRAS G12C inhibitors in trial
Next-Gen KRAS G12C Inhibition: The Rise of Elisrasib and Divarasib ...
The Evolution of KRAS G12C Inhibition in NSCLC: Divarasib vs. Standards ...
Divarasib - Wikipedia
Next-Gen KRAS G12C Inhibitors: Divarasib and Elisrasib in NSCLC ...
Roche-Aktie im Plus: Divarasib senkt Sterberisiko bei Lungenkrebs um 44 ...
divarasib
Table 1 from Single-Agent Divarasib (GDC-6036) in Solid Tumors with a ...
Divarasib in the Evolving Landscape of KRAS G12C Inhibitors for NSCLC - PMC
The Next Generation of KRAS G12C Inhibitors: Elisrasib and Divarasib ...
Divarasib Plus Cetuximab In Kras G12C – BZHV
Roche’s Divarasib Shows Superiority in Head-to-Head Phase III Trial ...
Genentech’s Divarasib Shows Superiority in Head-to-Head Phase III Trial ...
Genentech’s Divarasib Delivers Phase III Survival Benefit in KRAS G12C ...
(PDF) Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer ...
Divarasib Combo Appears “Promising” in Pretreated KRAS G12C+ NSCLC ...
(PDF) Divarasib in the Evolving Landscape of KRAS G12C Inhibitors for NSCLC
Divarasib in KRAS G12C NSCLC: Advancing Targeted Therapy in 2026 ...
Divarasib Displays Early-Phase Activity in KRAS G12C–Mutant Solid ...
Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C ...
Divarasib Intermediate-1 2417918-75-1
Full article: The structure of KRASG12C bound to divarasib highlights ...
Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a ...
Long-Term Follow-Up of Divarasib Alone in Patients with KRAS G12C Lung ...
Divarasib as Compared with Sotorasib or Adagrasib in KRAS G12C–Mutated ...
Divarasib Racemic 2417918-04-6
Single-Agent Divarasib in Patients With KRAS G12C–Positive Non–Small ...
P3.12D.07 Divarasib Versus Adagrasib or Sotorasib in Pretreated KRAS ...
616MO Long-term follow-up of single-agent divarasib in patients with ...
Genentech to Present Phase III Cancer Trial Data at ESMO 2026 ...
【Chugai Pharmaceutical FY2026 Q3 Earnings Call】Japan's Chugai ...
ESMO: Roche sees ph. 3 KRAS data ‘convincing health authorities’
ESMO 2026: Key KRAS Inhibitor Takeaways for Oncology Nurses | Oncology ...
New Standard-of-Care for KRAS G12C-Mutated Advanced NSCLC | Inside ...
Roche to present pivotal data at ESMO 2026, showcasing advances across ...
ESMO26: Roche's KRAS drug tops approved drugs in NSCLC | pharmaphorum
Chugai Q3 2026 slides: revenue up 17%, pipeline advances By Investing.com
The Rise of Divarasib: Next-Gen KRAS G12C Inhibition in NSCLC · Cancer ...
divarasib: A KRAS G12C inhibitor being evaluated in clinical studies ...
ESMO 2026 coverage: 34 videos | ConferenceHype
2026 ESMO丨全新一代KRAS G12C抑制剂：Divarasib以III期头对头全面获益，彰显KRAS G12C突变NSCLC后线治疗 ...
罗氏divarasib III期头对头数据亮相ESMO：总生存17.7个月对12个月完胜竞品 - B910化工
2026 ESMO 每日快报丨Krascendo 1研究显示divarasib较现有KRAS G12C抑制剂显著改善NSCLC患者PFS和OS ...
KRAS G12C，新一代靶向药Divarasib全面碾压Sotorasib/adagrasib - 知乎
Mohammad Vaziri on LinkedIn: Early promising results with the novel ...
既治療KRAS G12C変異NSCLC、divarasibがPFS・OSを改善（Krascendo 1）／ESMO2026｜医師向け医療 ...
دواء جديد يخفض خطر الوفاة 44% بسرطان الرئة
Nieuwe positieve fase III-resultaten voor Roche bij longkanker ...
Divarasib治疗KRAS G12C肺癌：PFS达13.8个月，新一代抑制剂疗效与副作用全解析 - MedFind
Genomic landscape of clinically acquired resistance alterations in ...
Roche Aktie: ESMO-Auftritt mit Schwergewichten
罗氏KRAS G12C抑制剂divarasib 1期临床试验结果积极 - 知乎
NEJM：单药Divarasib（GDC-6036）治疗KRAS G12C突变实体瘤-MedSci.cn
Divarasib在KRAS G12C突变肺癌中ORR超过50%！ – 阔然生物|阔然基因
Divarasib临床新进展：治疗KRAS G12C非小细胞肺癌的长期效果与安全性分析 - MedFind
NEJM：一骑绝尘！又一种KRAS突变抑制剂“亮剑”，治疗肺癌有效率超50%！_腾讯新闻
RCSB PDB - 9DMM: Crystal structure of human KRAS G12C covalently bound ...
